meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced hepatocellular cancer (mHCC)
mHCC - (neo)adjuvant (NA)
3
mHCC - 1st line (L1)
10
mHCC - 2nd line (L2)
2
lung cancer : non small cell (NSCLC)
5
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus bevacizumab
atezolizumab plus cabozantinib
camrelizumab based treatment
durvalumab based treatment
durvalumab plus bevacizumab
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab plus lenvatinib
sintilimab based treatment
sintilimab
Tislelizumab
Immune checkpoint association
durvalumab plus tremelimumab
nivolumab plus ipilimumab
nivolumab plus ipilimumab plus SoC
VEGF(R) inhibitor
bevacizumab based treatment
bevacizumab
versus all
vs chemotherapy
vs Standard of Care (SoC)
vs immune chekpoint inhibitors
vs anti-PD-(L)1
vs atezolizumab based treatment
vs atezolizumab plus bevacizumab
vs nivolumab based treatment
vs nivolumab alone
vs non active control
vs no additional treatment
vs placebo
vs VEGF(R) inhibitor
vs lenvatinib
vs sorafenib
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
sintilimab
title
Standard of Care (SoC)
title
sorafenib
title
Wang, 2024 ChiCTR2000037655 mHCC - (neo)adjuvant (NA) 99/99
ORIENT-32, 2021 NCT03794440 mHCC - 1st line (L1) 380/191
Pathology:
mHCC - (neo)adjuvant (NA);
mHCC - 1st line (L1);
mHCC - (neo)adjuvant (NA)
mHCC - 1st line (L1)
Wang, 2024
ORIENT-32, 2021
sintilimab
2
T1
T1
Standard of Care (SoC)
0
T0
sorafenib
0
T0